Edwards Lifesciences (NYSE:EW) Shares Break Above 200-Day Moving Average – What’s Next?

Edwards Lifesciences Corporation (NYSE:EW)’s share price passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $86.11 and traded as high as $87.57. Edwards Lifesciences shares last traded at $87.2850, with a volume of 3,315,836 shares.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on EW. Royal Bank Of Canada increased their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, July 13th. BTIG Research reaffirmed a “buy” rating and set a $110.00 price objective on shares of Edwards Lifesciences in a research note on Friday, September 11th. Truist Financial boosted their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Piper Sandler reissued an “overweight” rating and issued a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Finally, Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, September 26th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Price Performance

The stock has a 50 day moving average of $88.80 and a 200-day moving average of $86.13. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $49.30 billion, a P/E ratio of 49.21, a price-to-earnings-growth ratio of 2.29 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter in the prior year, the company posted $0.67 EPS. Edwards Lifesciences’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 544 shares of the company’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $91.06, for a total value of $49,536.64. Following the transaction, the senior vice president directly owned 14,868 shares in the company, valued at $1,353,880.08. This represents a 3.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel Lippis sold 619 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $87.51, for a total value of $54,168.69. Following the completion of the sale, the vice president owned 40,034 shares of the company’s stock, valued at $3,503,375.34. The trade was a 1.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 5,045 shares of company stock valued at $455,341 in the last three months. Company insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors have recently made changes to their positions in the company. Hanson & Doremus Investment Management purchased a new position in Edwards Lifesciences during the 1st quarter valued at about $25,000. MV Capital Management Inc. bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $26,000. RMG Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences in the 1st quarter worth approximately $26,000. Pin Oak Investment Advisors Inc. purchased a new stake in shares of Edwards Lifesciences in the 2nd quarter worth approximately $26,000. Finally, TrinityBridge Ltd bought a new position in shares of Edwards Lifesciences during the second quarter valued at approximately $27,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.